Fresh Tracks Therapeutics (NASDAQ:FRTX) vs. Tectonic Therapeutic (NASDAQ:TECX) Critical Contrast

Tectonic Therapeutic (NASDAQ:TECX) and Fresh Tracks Therapeutics (NASDAQ:FRTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Earnings & Valuation

This table compares Tectonic Therapeutic and Fresh Tracks Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	$12.16 million	($5.89)	-5.84
Fresh Tracks Therapeutics	$8.01 million	0.69	-$5.69 million	($1.41)	-0.66

Tectonic Therapeutic has higher earnings, but lower revenue than Fresh Tracks Therapeutics. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Fresh Tracks Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Tectonic Therapeutic and Fresh Tracks Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	0	0	5	1	3.17
Fresh Tracks Therapeutics	0	0	0	0	0.00

Tectonic Therapeutic presently has a consensus price target of $80.50, suggesting a potential upside of 133.88%. Given Tectonic Therapeutic’s stronger consensus rating and higher probable upside, analysts clearly believe Tectonic Therapeutic is more favorable than Fresh Tracks Therapeutics.

Volatility & Risk

Tectonic Therapeutic has a beta of 2.62, suggesting that its stock price is 162% more volatile than the S&P 500. Comparatively, Fresh Tracks Therapeutics has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500.

Profitability

This table compares Tectonic Therapeutic and Fresh Tracks Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-35.53%	-31.97%
Fresh Tracks Therapeutics	N/A	N/A	N/A

Insider and Institutional Ownership

62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 25.0% of Fresh Tracks Therapeutics shares are owned by institutional investors. 9.2% of Tectonic Therapeutic shares are owned by insiders. Comparatively, 0.2% of Fresh Tracks Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Tectonic Therapeutic beats Fresh Tracks Therapeutics on 8 of the 13 factors compared between the two stocks.

About Tectonic Therapeutic

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

About Fresh Tracks Therapeutics

Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.